Macrophages, oxysterols and atherosclerosis

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2045-2051

  Shibata, Norihito ^a   Glass, Christopher K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cholesterol; Cytokines

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACYL COENZYME A DESATURASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASPASE 3; CHOLESTEROL; FAS ANTIGEN; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; OXYSTEROL; PROTEIN BAX; RETINOID X RECEPTOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR PU 1; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CYTOTOXICITY; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; IMMUNITY; MACROPHAGE; REVIEW; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; HUMANS; MACROPHAGES; RECEPTORS, STEROID; STEROLS;

EID: 77958057683     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0860     Document Type: Review

References (77)

1. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006; 6: 508-519.
2. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
3. Dworacka M, Winiarska H, Borowska M, Abramczyk M, Bobkiewicz-Kozlowska T, Dworacki G. Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ J 2007; 71: 962-967.
4. Shimada K. Immune system and atherosclerotic disease: Heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009; 73: 994-1001.
5. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
6. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
7. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261.
8. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
9. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol 2002; 13: 373-381.
10. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007; 117: 2216-2224.
11. Yvan-Charvet L, Ranalletta M, Wang N, Han S, Terasaka N, Li R, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007; 117: 3900-3908.
12. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
13. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell 2001; 104: 503-516.
14. Alkazemi D, Egeland G, Vaya J, Meltzer S, Kubow S. Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J Clin Endocrinol Metab 2008; 93: 4282-4289.
15. Murakami H, Tamasawa N, Matsui J, Yamato K, JingZhi G, Suda T. Plasma levels of soluble vascular adhesion molecule-1 and cholesterol oxidation product in type 2 diabetic patients with nephropathy. J Atheroscler Thromb 2001; 8: 21-24.
16. Olkkonen VM, Lehto M. Oxysterols and oxysterol binding proteins: Role in lipid metabolism and atherosclerosis. Ann Med 2004; 36: 562-572.
17. Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, et al. Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free Radic Res 2001; 34: 485-497.
18. Zieden B, Kaminskas A, Kristenson M, Kucinskiene Z, Vessby B, Olsson AG, et al. Increased plasma 7 beta-hydroxycholesterol concentrations in a population with a high risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 967-971.
19. Carpenter KL, Wilkins GM, Fussell B, Ballantine JA, Taylor SE, Mitchinson MJ, et al. Production of oxidized lipids during modification of low-density lipoprotein by macrophages or copper. Biochem J 1994; 304: 625-633.
20. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: Evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001; 276: 38685-38689.
21. Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase: A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 1991; 266: 7774-7778.
22. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 1998; 273: 34316-34327.
23. Rowe AH, Argmann CA, Edwards JY, Sawyez CG, Morand OH, Hegele RA, et al. Enhanced synthesis of the oxysterol 24(S),25- epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene: Lanosterol cyclase: A novel mechanism for the attenuation of foam cell formation. Circ Res 2003; 93: 717-725.
24. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci USA 1999; 96: 266-271.
25. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007; 25: 57-70.
26. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325: 100-104.
27. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein- 1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-2830.
28. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-2838.
29. Qin Y, Dalen KT, Gustafsson JA, Nebb HI. Regulation of hepatic fatty acid elongase 5 by LXRalpha-SREBP-1c. Biochim Biophys Acta 2009; 1791: 140-147.
30. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992; 68: 397-406.
31. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000; 5: 289-298.
32. de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000; 290: 2140-2144.
33. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 1995; 9: 1033-1045.
34. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
35. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219.
36. Ogawa S, Lozach J, Jepsen K, Sawka-Verhelle D, Perissi V, Sasik R, et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci USA 2004; 101: 14461-14466.
37. Venteclef N, Jakobsson T, Ehrlund A, Damdimopoulos A, Mikkonen L, Ellis E, et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev 2010; 24: 381-395.
38. Ghisletti S, Huang W, Jepsen K, Benner C, Hardiman G, Rosenfeld MG, et al. Cooperative NCoR/SMRT interactions establish a corepressor- based strategy for integration of inflammatory and antiinflammatory signaling pathways. Genes Dev 2009; 23: 681-693.
39. Huang W, Ghisletti S, Perissi V, Rosenfeld MG, Glass CK. Transcriptional integration of TLR2 and TLR4 signaling at the NCoR depresssion checkpoint. Mol Cell 2009; 35: 48-57.
40. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276: 38378-38387.
41. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: Potential new players in atherosclerosis. Nat Med 2002; 8: 1243-1248.
42. Marathe C, Bradley MN, Hong C, Lopez F, Ruiz de Galarreta CM, Tontonoz P, et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. J Biol Chem 2006; 281: 32197-32206.
43. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009; 31: 245-258.
44. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008; 134: 97-111.
45. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 2007; 104: 6511-6518.
46. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
47. Radhakrishnan A, Sun LP, Kwon HJ, Brown MS, Goldstein JL. Direct binding of cholesterol to the purified membrane region of SCAP: Mechanism for a sterol-sensing domain. Mol Cell 2004; 15: 259-268.
48. Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell 2002; 10: 237-245.
49. Espenshade PJ, Li WP, Yabe D. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proc Natl Acad Sci USA 2002; 99: 11694-11699.
50. Wyles JP, McMaster CR, Ridgway ND. Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum. J Biol Chem 2002; 277: 29908-29918.
51. Lehto M, Hynynen R, Karjalainen K, Kuismanen E, Hyvarinen K, Olkkonen VM. Targeting of OSBP-related protein 3 (ORP3) to endoplasmic reticulum and plasma membrane is controlled by multiple determinants. Exp Cell Res 2005; 310: 445-462.
52. Wyles JP, Ridgway ND. VAMP-associated protein-A regulates partitioning of oxysterol-binding protein-related protein-9 between the endoplasmic reticulum and Golgi apparatus. Exp Cell Res 2004; 297: 533-547.
53. Johansson M, Bocher V, Lehto M, Chinetti G, Kuismanen E, Ehnholm C, et al. The two variants of oxysterol binding proteinrelated protein-1 display different tissue expression patterns, have different intracellular localization, and are functionally distinct. Mol Biol Cell 2003; 14: 903-915.
54. Rocha N, Kuijl C, van der Kant R, Janssen L, Houben D, Janssen H, et al. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. J Cell Biol 2009; 185: 1209-1225.
55. Hynynen R, Suchanek M, Spandl J, Back N, Thiele C, Olkkonen VM. OSBP-related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism of neutral lipids. J Lipid Res 2009; 50: 1305-1315.
56. Wang PY, Weng J, Anderson RG. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 2005; 307: 1472-1476.
57. Bowden K, Ridgway ND. OSBP negatively regulates ABCA1 protein stability. J Biol Chem 2008; 283: 18210-18217.
58. Yan D, Mayranpaa MI, Wong J, Perttila J, Lehto M, Jauhiainen M, et al. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. J Biol Chem 2008; 283: 332-340.
59. Yan D, Jauhiainen M, Hildebrand RB, Willems van Dijk K, Van Berkel TJ, Ehnholm C, et al. Expression of human OSBP-related protein 1L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1618-1624.
60. Taylor FR, Saucier SE, Shown EP, Parish EJ, Kandutsch AA. Correlation between oxysterol binding to a cytosolic binding protein and potency in the repression of hydroxymethylglutaryl coenzyme A reductase. J Biol Chem 1984; 259: 12382-12387.
61. Brown AJ, Leong SL, Dean RT, Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 1997; 38: 1730-1745.
62. Bjorkhem I, Andersson O, Diczfalusy U, Sevastik B, Xiu RJ, Duan C, et al. Atherosclerosis and sterol 27-hydroxylase: Evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci USA 1994; 91: 8592-8596.
63. Crisby M, Nilsson J, Kostulas V, Bjorkhem I, Diczfalusy U. Localization of sterol 27-hydroxylase immuno-reactivity in human atherosclerotic plaques. Biochim Biophys Acta 1997; 1344: 278-285.
64. Smith LL, Van Lier JE. Sterol metabolism: 9.26-hydroxycholesterol levels in the human aorta. Atherosclerosis 1970; 12: 1-14.
65. Carpenter KL, Taylor SE, Ballantine JA, Fussell B, Halliwell B, Mitchinson MJ. Lipids and oxidised lipids in human atheroma and normal aorta. Biochim Biophys Acta 1993; 1167: 121-130.
66. Carpenter KL, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta 1995; 1256: 141-150.
67. Carpenter KL, Taylor SE, van der Veen C, Mitchinson MJ. Evidence of lipid oxidation in pulmonary artery atherosclerosis. Atherosclerosis 1995; 118: 169-172.
68. Palozza P, Serini S, Verdecchia S, Ameruso M, Trombino S, Picci N, et al. Redox regulation of 7-ketocholesterol-induced apoptosis by beta-carotene in human macrophages. Free Radic Biol Med 2007; 42: 1579-1590.
69. Biasi F, Leonarduzzi G, Vizio B, Zanetti D, Sevanian A, Sottero B, et al. Oxysterol mixtures prevent proapoptotic effects of 7-ketocholesterol in macrophages: Implications for proatherogenic gene modulation. FASEB J 2004; 18: 693-695.
70. Prunet C, Lemaire-Ewing S, Menetrier F, Neel D, Lizard G. Activation of caspase-3-dependent and -independent pathways during 7-ketocholesterol- and 7beta-hydroxycholesterol-induced cell death: A morphological and biochemical study. J Biochem Mol Toxicol 2005; 19: 311-326.
71. Ryan L, O'Callaghan YC, O'Brien NM. Comparison of the apoptotic processes induced by the oxysterols 7beta-hydroxycholesterol and cholesterol-5beta,6beta-epoxide. Cell Biol Toxicol 2004; 20: 313-323.
72. Lim HK, Kang HK, Yoo ES, Kim BJ, Kim YW, Cho M, et al. Oxysterols induce apoptosis and accumulation of cell cycle at G(2)/M phase in the human monocytic THP-1 cell line. Life Sci 2003; 72: 1389-1399.
73. Rusinol AE, Thewke D, Liu J, Freeman N, Panini SR, Sinensky MS. AKT/protein kinase B regulation of BCL family members during oxysterol-induced apoptosis. J Biol Chem 2004; 279: 1392-1399.
74. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
75. Lordan S, Mackrill JJ, O'Brien NM. Involvement of Fas signalling in 7beta-hydroxycholesterol-and cholesterol-5beta,6beta-epoxideinduced apoptosis. Int J Toxicol 2008; 27: 279-285.
76. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004; 119: 299-309.
77. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci USA 2004; 101: 17813-17818.